Source comparison
CJC-1295 No DAC & Ipamorelin Safety Studies — Comparison
CJC-1295 No DAC (Mod GRF 1–29) GHRH analog. Stimulates pituitary somatotrophs directly ~30 minutes Transient facial flushing, mild injection site reactions, occasional headache None beyond 16 weeks Phase II (completed in aging populations; no Phase III trials
This comparison does not assign a generated winner or score.
- CJC-1295 No DAC (Mod GRF 1–29)
- GHRH analog. Stimulates pituitary somatotrophs directly
- ~30 minutes
- Transient facial flushing, mild injection site reactions, occasional headache
- None beyond 16 weeks
- Phase II (completed in aging populations; no Phase III trials published)
- Ipamorelin
- GHRP. Selective ghrelin receptor agonist
- ~2 hours (GH elevation peaks at 30–45 min)
- Mild transient hunger, occasional injection site erythema, rare dizziness
- Phase II (completed; no Phase III trials examining long-term safety)
- CJC-1295/Ipamorelin Stack
- Synergistic GH release via complementary pathways
- N/A (both peptides administered together)
- Side effects mirror individual peptide profiles. No additive SAEs documented in clinical observation
- None. No formal combination trials exist
- Observational data only. No controlled trials
- Tesamorelin (FDA-approved GHRH analog)
- GHRH analog (similar mechanism to CJC-1295 No DAC)
- ~26–38 minutes
- Injection site reactions, arthralgia, peripheral edema
- FDA-approved for HIV-associated lipodystrophy. 26-week pivotal trials
- Phase III completed; FDA-approved 2010
- Professional Assessment
- The absence of Phase III combination trials means safety assumptions are extrapolated from individual peptide data and clinical observation. The synergy is pharmacologically sound, but formal long-term safety validation is missing. Users should weigh known individual peptide tolerability against the lack of dedicated combination research.